The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial

Inclusion Criteria:

- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage
I-III), who are

- between 18 and 75 years old,

- have a body mass index (BMI) between 18 and 35 kg/m^2,

- and are eligible for laparoscopically-assisted colectomy for primary tumor resection.

- Patients must have the ability to understand and the willingness to sign a written
informed consent document.

Exclusion Criteria:

- A history of allergic-type reactions to celecoxib or sulphonamides,

- a history of asthma, skin reactions or other allergic reactions to aspirin or other
NSAIDs,

- a history of thromboembolic event (cerebrovascular accident, transient ischemic
attack,

- unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),

- renal insufficiency (defined by a serum creatinine level > 1.5 mg/dL or blood urea
nitrogen level > 22 mg/dL),

- active gastrointestinal bleeding in the 60 days before surgery,

- alcohol or drug abuse, and

- previous chemotherapy or abdominal/pelvic radiation therapy.

- After randomization, other exclusion criteria will include a surgical procedure
longer than 6 h, inability to extubate the trachea within 4 h after operation,
evidence of a new postoperative myocardial infarction, abnormal postoperative mental
status or any new neurologic deficit, significant postoperative bleeding (with a
hemoglobin level < 7.5 g/dL), requiring blood transfusion, or a urine output of less
than 30 mL/h.